[{"orgOrder":0,"company":"Neurotrope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"Protein kinase C (PRKC)","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurotrope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ Inapplicable"},{"orgOrder":0,"company":"Neurotrope","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"Protein kinase C (PRKC)","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurotrope \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ National Institutes of Health"},{"orgOrder":0,"company":"Neurotrope","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Bryostatin-1","moa":"Protein kinase C (PRKC)","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurotrope \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ National Institutes of Health"},{"orgOrder":0,"company":"Neurotrope","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"Protein kinase C (PRKC)","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurotrope \/ Neurotrope","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ Neurotrope"},{"orgOrder":0,"company":"Neurotrope","sponsor":"BryoLogyx Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"Protein kinase C (PRKC)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurotrope \/ BryoLogyx Inc","highestDevelopmentStatusID":"5","companyTruncated":"Neurotrope \/ BryoLogyx Inc"},{"orgOrder":0,"company":"Neurotrope","sponsor":"Petros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Avanafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurotrope \/ Neurotrope","highestDevelopmentStatusID":"15","companyTruncated":"Neurotrope \/ Neurotrope"},{"orgOrder":0,"company":"Neurotrope","sponsor":"National Institutes of Health | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurotrope \/ National Institutes of Health | National Institute on Aging","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ National Institutes of Health | National Institute on Aging"}]

Find Clinical Drug Pipeline Developments & Deals by Neurotrope

Neurotrope
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check all FDF Dossiers for
this supplier

Contact Us
PharmaScopic.com

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Neurotrope

U.S.A

Vitafoods

Not Confirmed

02

Neurotrope

U.S.A

Vitafoods

Not Confirmed

03

Neurotrope

U.S.A

Vitafoods

Not Confirmed

04

Neurotrope

U.S.A

Vitafoods

Not Confirmed

05

Neurotrope

U.S.A

Vitafoods

Not Confirmed

06

Neurotrope

U.S.A

Vitafoods

Not Confirmed

07

Neurotrope

U.S.A

Vitafoods

Not Confirmed

08

Neurotrope

U.S.A

Vitafoods

Not Confirmed

09

Neurotrope

U.S.A

Vitafoods

Not Confirmed

10

Neurotrope

U.S.A

Vitafoods

Not Confirmed